Merck & Co. Inc. (MRK)

69.88
0.29 0.41
NYSE : Health Technology
Prev Close 70.17
Open 70.21
Day Low/High 69.93 / 70.23
52 Wk Low/High 52.83 / 70.22
Volume 496.99K
Avg Volume 9.09M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 183.67B
EPS 0.90
P/E Ratio 138.12
Div & Yield 1.92 (2.77%)
Apple, BP, Boeing, Pfizer and Merck - 5 Things You Must Know

Apple, BP, Boeing, Pfizer and Merck - 5 Things You Must Know

U.S. stock futures are mixed as the Federal Reserve kicks off a two-day meeting and Apple is scheduled to report quarterly results.

Wall Street Futures Edge Lower, Oil Holds Gains; Markets Await Apple Earnings

Wall Street Futures Edge Lower, Oil Holds Gains; Markets Await Apple Earnings

Global stocks bumped higher Tuesday, while oil prices held at three-and-a-half year highs, amid several key market closures and ahead of what could be a crucial quarterly earnings update from Apple after the close of trading.

Are Apple's Best Days in the Past?: Market Recon

Are Apple's Best Days in the Past?: Market Recon

I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.

Financial Highlights Package

Financial Highlights Package

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2018.

Fighting Crosswinds: Cramer's 'Mad Money' Recap (Friday 4/27/18)

Fighting Crosswinds: Cramer's 'Mad Money' Recap (Friday 4/27/18)

Jim Cramer says foolish traders believe a trade war will trigger a recession, but they're wrong. Fight the crosswinds with a game plan for next week.

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

The drugmakers and health insurer are preparing to unveil first-quarter numbers.

European Medicines Agency Validates Type II Variation For Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed (ALIMTA®) And Platinum Chemotherapy As First-Line Therapy In Metastatic Nonsquamous NSCLC, Based On Phase 3 KEYNOTE-189 Trial

European Medicines Agency Validates Type II Variation For Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed (ALIMTA®) And Platinum Chemotherapy As First-Line Therapy In Metastatic Nonsquamous NSCLC, Based On Phase 3 KEYNOTE-189 Trial

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the company's Type II Variation, which seeks approval for...

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.

Intermediate Trade: Merck

Intermediate Trade: Merck

2018 should be the beginning of Merck's earnings return to growth.

Asia Benchmarks Sag; U.S. Stock Futures Edge Higher

Asia Benchmarks Sag; U.S. Stock Futures Edge Higher

Asia markets traded mostly lower Tuesday, with Hong Kong's benchmark down almost 500 points.

Dow Jumps 212 Points as Wall Street Shrugs Off Syria and Turns to Earnings

Dow Jumps 212 Points as Wall Street Shrugs Off Syria and Turns to Earnings

Stocks rise Monday as concerns over prolonged military action in Syria fade and the focus for investors shifts to a heavy upcoming slate of U.S. corporate earnings.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

The Worst Stock Market Plunge in Your Lifetime Is Coming: Jim Rogers

The Worst Stock Market Plunge in Your Lifetime Is Coming: Jim Rogers

Legendary investor Jim Rogers thinks the market is headed straight for a major sell off. Here's why.

Jim's Daily Rundown

Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!

Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data

Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data

The drugmakers on April 16 released data from their respective studies at the Association for Cancer Research's annual meeting in Chicago.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks Rise on Softer U.S. Approach in China Trade War

Stocks rise Monday following tweets from Donald Trump that appeared to indicate the U.S. was softening its approach in its trade battle with China.

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Stock Futures Are on a Mild Tear Monday After Brutal Friday Selloff

Markets around the globe last week were tumultuous after both China and the U.S. proposed tariffs on imported goods as investors weigh whether the countries will come to the table to negotiate an end to the spat.

Incyte And Merck Provide Update On Phase 3 Study Of Epacadostat In Combination With KEYTRUDA® (pembrolizumab) In Patients With Unresectable Or Metastatic Melanoma

Incyte And Merck Provide Update On Phase 3 Study Of Epacadostat In Combination With KEYTRUDA® (pembrolizumab) In Patients With Unresectable Or Metastatic Melanoma

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that an external Data Monitoring Committee (eDMC) review of the pivotal Phase 3 ECHO-301/KEYNOTE-252...

The European Medicines Agency Accepts Regulatory Submission For LYNPARZA® (olaparib) In BRCA-Mutated HER2-Negative Metastatic Breast Cancer

The European Medicines Agency Accepts Regulatory Submission For LYNPARZA® (olaparib) In BRCA-Mutated HER2-Negative Metastatic Breast Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the US and Canada, today announced that the European Medicines Agency has validated for review the Marketing Authorization Application (MAA) for LYNPARZA ®...

Merck To Hold First-Quarter 2018 Sales And Earnings Conference Call On May 1

Merck To Hold First-Quarter 2018 Sales And Earnings Conference Call On May 1

Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.

Trump's Amazon Assault Shows He Can't Leave Well Enough Alone

Trump's Amazon Assault Shows He Can't Leave Well Enough Alone

The basic features of a prosperous corporate environment are all around us, but it's become difficult to stick to that narrative amid all the diversions, including from the President.

Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick

Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc is the #12 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Merck & Co Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #187 spot out of 500.

Http://www.merck.com

Http://www.merck.com

Eisai Co., Ltd.

Merck Announces Appointment Of Jennifer Zachary As General Counsel

Merck Announces Appointment Of Jennifer Zachary As General Counsel

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018.

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Watch for these upstart names to topple some big-caps going forward.

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Jim Cramer focuses on Merck, Eli Lilly, Abbott Labs, Phillips 66, Five Below, and Cintas in the Lightning Round.

TheStreet Quant Rating: B+ (Buy)